What is the current stock price of NeuroPace, Inc. (NPCE)?

As of the latest market data, NeuroPace, Inc. (NPCE) is trading at $14.26. The stock has seen a loss of -2.66% today.

Does NeuroPace, Inc. (NPCE) pay a dividend?

Based on current data, NeuroPace, Inc. does not have a confirmed active dividend policy.

What is the market cap of NeuroPace, Inc.?

The current market capitalization of NeuroPace, Inc. (NPCE) is approximately unavailable.

NPCE

NeuroPace, Inc.·Healthcare

14.26

2.662%(−0.39)

Market Closed

17.50

22.721%(+3.24)

After Hours

Last Updated: — ET

52W L: $7.5652W H: $18.98

NPCE NEWS

businesswire.com

1d ago

NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 25th Annual Needham Virtual Healthcare Conference at 1:30pm ET (10:30am PT) on Tuesday, April 14, 2026. Management will also host investor meetings during the conference. The presentation will be accessible via live webcast here. A webcast replay will be available for thirty.

defenseworld.net

6d ago

Contrasting NeuroPace (NASDAQ:NPCE) & Integer (NYSE:ITGR)

Integer (NYSE: ITGR - Get Free Report) and NeuroPace (NASDAQ: NPCE - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends. Insider and Institutional Ownership 99.3% of Integer shares are held

zacks.com

Apr 2

NeuroPace (NPCE) Up 0.9% Since Last Earnings Report: Can It Continue?

NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?

zacks.com

Apr 2

Here's Why You Should Add NeuroPace Stock to Your Portfolio Now

NPCE rides strong RNS adoption and AI innovation, but near-term profitability faces pressure as IGE expansion and revenue contribution remain uncertain.

zacks.com

Apr 2

Wall Street Analysts See a 41.29% Upside in NeuroPace (NPCE): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 41.3% in NeuroPace (NPCE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

defenseworld.net

Apr 1

NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of “Moderate Buy” from Brokerages

NeuroPace, Inc. (NASDAQ: NPCE - Get Free Report) has been given an average rating of "Moderate Buy" by the eight analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and two have given a

Company Profile

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.

Sector

Healthcare

Industry

Medical - Devices

Employees

184

IPO Date

2021-04-22

Beta

1.88

Websitewww.neuropace.com↗